Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of BR1010 vs Co-administration of Fimasartan/Amlodipine and Hydrochlorothiazide
NCT03629067Phase 1Completed
- Sponsor
- Boryung
- Start
- Sep 2018
- Primary completion
- Nov 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of fimasartan, amlodipine and hydrochlorothiazide in hypertension (HTN) (3 arms), sponsored by Boryung. Primary endpoint: Maximum Plasma Concentration. Started Sep 2018; status: completed.
02
Drugs
fimasartanamlodipinehydrochlorothiazide
03
Conditions
hypertension (HTN)
Beyond the preview
Go deeper on NCT03629067.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03629067.